

**UCC Library and UCC researchers have made this item openly available.
Please [let us know](#) how this has helped you. Thanks!**

Title	Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial
Author(s)	Mone, Fionnuala; Mulcahy, Cecilia; McParland, Peter; Breathnach, Fionnuala M.; Downey, Paul; McCormack, Dorothy; Culliton, Marie; Stanton, Alice; Cody, Fiona; Morrison, John J.; Daly, Sean; Higgins, John R.; Cotter, Amanda; Hunter, Alyson; Tully, Elizabeth C.; Dicker, Patrick; Alfirevic, Zarko; Malone, Fergal D.; McAuliffe, Fionnuala M.
Publication date	2018
Original citation	Mone, F., Mulcahy, C., McParland, P., Breathnach, F., Downey, P., McCormack, D., Culliton, M., Stanton, A., Cody, F., Morrison, J. J., Daly, S., Higgins, J., Cotter, A., Hunter, A., Tully, E. C., Dicker, P., Alfirevic, Z., Malone, F. D. and McAuliffe, F. M. (2018) 'Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial', <i>BMJ Open</i> , 8(7), e022056 (9pp). doi: 10.1136/bmjopen-2018-022056
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://bmjopen.bmj.com/content/8/7/e022056 http://dx.doi.org/10.1136/bmjopen-2018-022056 Access to the full text of the published version may require a subscription.
Rights	© 2018, the Author(s) (or their employer(s)). This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . http://creativecommons.org/licenses/by-nc/4.0/
Item downloaded from	http://hdl.handle.net/10468/6940



Downloaded on 2019-10-18T09:12:54Z

Outcome	Screen positive; Aspirin Group 3A N=13	Screen negative; No Aspirin Group 3B N=171	OR (95% CI)
Preeclampsia No. (%)	2 (15.4)	6 (3.5)	5.0 (0.9 – 27.7)
Pre-eclampsia <34-weeks	0 (0)	2 (1.2)	-
Pre-eclampsia <37-weeks	2 (15.4)	2 (1.2)	15.4 (2.0 – 120)
Birthweight <10 th centile No. (%)	4 (30.7)	21 (12.3)	3.2 (0.9 – 11.2)
Pre-term delivery <34 weeks No. (%)	1 (7.7)	1 (0.6)	14.1 (0.8 – 240)
NICU admission No. (%)	0 (0)	9 (5.3)	-
Outcome No. (%)			
Alive at 6-weeks	13 (100)	169 (98.8)	
Stillbirth	0 (0)	2 (1.2)	
Neonatal death	0 (0)	0 (0)	

Table S2 - Secondary outcome measures in Group 3 (screen and treat)

(Expressed as average and standard deviation unless otherwise stated)

Note: ORs are not presented when number of events is 0 in the Screen –positive group.